3.85
+0.07(+1.85%)
Currency In USD
| Previous Close | 3.78 |
| Open | 3.69 |
| Day High | 3.95 |
| Day Low | 3.69 |
| 52-Week High | 5.9 |
| 52-Week Low | 0.6 |
| Volume | 1.06M |
| Average Volume | 2.17M |
| Market Cap | 315.03M |
| PE | -7.7 |
| EPS | -0.5 |
| Moving Average 50 Days | 3.74 |
| Moving Average 200 Days | 1.86 |
| Change | 0.07 |
If you invested $1000 in I-Mab (IMAB) since IPO date, it would be worth $308 as of October 01, 2025 at a share price of $3.85. Whereas If you bought $1000 worth of I-Mab (IMAB) shares 3 years ago, it would be worth $969.77 as of October 01, 2025 at a share price of $3.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments
GlobeNewswire Inc.
Sep 08, 2025 12:30 PM GMT
Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to followReiterates expectations to repor
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee
GlobeNewswire Inc.
Aug 25, 2025 11:00 AM GMT
Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of DirectorsResearch and Development Committee established to accelerate innovation and long-term growthDr. Ken Takeshita appointed to the Scientific Advisory Board ROCKVILLE, Md.,
I-Mab to Participate in September Investor Conferences
GlobeNewswire Inc.
Aug 21, 2025 11:00 AM GMT
ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s m